Publications by authors named "Lisa Egerer"

Claim this Profile
A
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.
Catherine Dold, Carles Rodriguez Urbiola, Guido Wollmann, Lisa Egerer, Alexander Muik

Mol Ther Oncolytics· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C peptides as entry inhibitors for gene therapy.
Lisa Egerer, Hans-Peter Kiem, Dorothee von Laer

Adv Exp Med Biol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.
Reinhard Tober, Zoltan Banki, Lisa Egerer, Alexander Muik, Sandra Behmüller

J Virol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.
Frances Brauer, Kerstin Schmidt, Roland C Zahn, Cornelia Richter, Heinfried H Radeke, Lisa Egerer

Antimicrob Agents Chemother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection.
Lisa Egerer, Andreas Volk, Joerg Kahle, Janine Kimpel, Frances Brauer

Mol Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
Felix G Hermann, Lisa Egerer, Frances Brauer, Christian Gerum, Harald Schwalbe

J Virol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis